Lanreotide Zentiva

Lanreotide, the active ingredient in Lanreotide Zentiva, is a somatostatin analog presented as a subcutaneous formulation for injection use. It is employed to control excess growth hormone secretion in acromegaly and to manage hormone‑related symptoms of neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Lanreotide is used in endocrine disorders that involve excess hormone secretion.

Acromegaly: reduces elevated growth hormone and IGF‑1 levels, improving clinical symptoms. Neuroendocrine tumors: controls hormone‑related symptoms such as flushing and diarrhoea and may inhibit tumor progression. Carcinoid syndrome associated with neuroendocrine tumors: alleviates flushing, abdominal pain and diarrhoea.

Lanreotide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema - Nausea - Diarrhoea - Headache

Serious or Rare Side Effects: - Gallstone formation - Pancreatitis - Severe hypersensitivity reactions including anaphylaxis - Severe hyperglycaemia requiring medical intervention

Before initiating therapy, consider the following precautions.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: assess liver enzymes regularly. Diabetes mellitus: observe blood glucose levels for possible hyperglycaemia. Gallbladder disease: evaluate risk of gallstone development. Pregnancy: safety not established; use only if benefits outweigh risks. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Octreotide or other somatostatin analogs: additive hormone suppression may increase adverse effects. - Cyclosporine: may exacerbate hyperglycaemia. - Antidiabetic agents: may require dose adjustment due to altered glucose control.

Moderate Interactions (Monitor Closely): - Beta‑blockers: can mask hypoglycaemia symptoms. - ACE inhibitors: monitor blood pressure for additive effects. - Warfarin: observe INR for potential changes.